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Introduction: Prevalence of iron deficiency (ID) at intensive care (ICU) admission is around 25 to 40%. Blood losses
are important during ICU stay, leading to iron losses, but prevalence of ID at ICU discharge is unknown. ID has
been associated with fatigue and muscular weakness, and may thus impair post-ICU rehabilitation. This study
assessed ID prevalence at ICU discharge, day 28 (D28) and six months (M6) after and its relation with fatigue.
Methods: We conducted this prospective, multicenter observational study at four University hospitals ICUs. Anemic
(hemoglobin (Hb) less than 13 g/dL in male and less than 12 g/dL in female) critically ill adult patients hospitalized
for at least five days had an iron profile taken at discharge, D28 and M6. ID was defined as ferritin less than 100 ng/L
or less than 300 ng/L together with a transferrin saturation less than 20%. Fatigue was assessed by numerical scale and
the Multidimensional Fatigue Inventory-20 questionnaire at D28 and M6 and muscular weakness by a hand grip test
at ICU discharge.
Results: Among 107 patients (men 77%, median (IQR) age 63 (48 to 73) years) who had a complete iron profile at ICU
discharge, 9 (8.4%) had ID. At ICU discharge, their hemoglobin concentration (9.5 (87.7 to 10.3) versus 10.2 (92.2 to 11.7)
g/dL, P =0.09), hand grip strength (52.5 (30 to 65) versus 49.5 (15.5 to 67.7)% of normal value, P =0.61) and visual
analog scale fatigue scale (57 (40 to 80) versus 60 (47.5 to 80)/100, P =0.82) were not different from non-ID patients.
At D28 (n =80 patients) and M6 (n =78 patients), ID prevalence increased (to 25 and 35% respectively) while anemia
prevalence decreased (from 100% to 80 and 25% respectively, P <0.0001). ID was associated with increased fatigue at
D28, after adjustment for main confounding factors, including anemia (regression coefficient (95%CI), 3.19 (0.74 to 5.64),
P =0.012). At M6, this association disappeared.
Conclusions: The prevalence of ID increases from 8% at discharge to 35% six months after prolonged ICU stay
(more than five days). ID was associated with increased fatigue, independently of anemia, at D28.Introduction
Anemia is a frequent disorder in critically ill patients
[1,2] and iron deficiency (ID) is known as the first cause of
anemia worldwide [3]. However, ID has rarely been inves-
tigated in critically ill patients [4-6]. Our knowledge of
iron metabolism was recently improved with the discovery* Correspondence: sigismond@lasocki.com
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iron metabolism in critically ill patients [6].
Available studies have investigated ID in critically ill pa-
tients mainly on intensive care unit (ICU) admission [7-14].
In these studies, the prevalence of ID was relatively high,
seen in 25% to 40% of the patients. In addition, blood loss
(and, therefore, iron loss) is known to be significant during
an ICU stay. Indeed, the mean daily volume of blood sam-
pling is estimated from 27 to 40 ml/day [1,14,15] and the
median volume of daily blood loss (estimated according to
hematocrit variation) during an ICU stay has been evaluatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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could represent a direct iron loss as high as 64 mg/day. In
addition, because of the inflammatory response usually ob-
served in critically ill patients, hepcidin levels are expected
to be increased, leading to an impairment of dietary iron ab-
sorption (thereby impairing the physiological pathway for
ID correction) [6]. One could therefore expect high ID
prevalence on ICU discharge. However, to the best of our
knowledge, there are no data available.
ID is a cause of anemia, but it is also responsible for
fatigue and muscular weakness (with or without anemia),
which can impair a patient's recovery. For example, in-
creased fatigue has been reported after cardiac surgery in
patients with ID, compared with non-ID patients [16].
Importantly, this link between ID and fatigue appears to
be independent of anemia in animal studies [17,18] and in
clinical reports [19]. Correction of ID after an ICU stay
can also be prolonged since physiological iron uptake is
quite low (approximately 1 to 2 mg/day) vis-à-vis the esti-
mated iron deficit. One could therefore speculate that ID
is frequent in critically ill patients and persists over time
after ICU discharge. It could also be responsible for
fatigue following ICU discharge.
The main objective of this study was to assess the preva-
lence of ID on ICU discharge and after (until six months
after discharge) and to assess the relation between iron
deficiency and fatigue.
Material and methods
This prospective multicenter observational study was ap-
proved by the ethics committee of Angers University Hos-
pital (approval N° 2011-28). All adult patients hospitalized
for at least five days in one of the four participating surgical
ICUs of the AtlanREA Group were included in the screen-
ing process (see [20] for participating center details). An
informational letter was given after an oral explanation. All
of the patients gave their informed consent. Patients with
anemia defined by World Health Organization criteria (that
is, hemoglobin (Hb) less than 12 g/dL in women or less
than 13 g/dl in men) were approached on ICU discharge to
give their informed consent. Patients who were unable to
answer questions or who had a known iron metabolism
disease were excluded. Other exclusion criteria were:
chronic anemia (hemoglobin ≤10 g/dL for more than three
months), current chemotherapy and estimated survival
of fewer than 28 days. The guidelines for blood transfu-
sion were based on French guidelines. Hemoglobin trig-
gers were 8 g/dl in the case of multiple comorbidities and
7 g/dl for all other patients.
Data collection
Data derived from medical charts were collected for all con-
senting patients, including age, gender, type of admission
(postoperative, unplanned surgical or medical), SimplifiedAcute Physiology Score II (SAPS II) and Sequential Organ
Failure Assessment (SOFA) for the first 24 hours following
ICU admission and body mass index. Significant comorbidi-
ties were also recorded, such as history of gastroduodenal
ulcer, cancer and alcoholism. Factors that could interfere
with iron metabolism, nutritional state or with neuromuscu-
lar weakness were recorded: iron administration, blood
transfusion, corticosteroids, vasopressor use, parenteral nu-
trition, renal replacement therapy and length of mechanical
ventilation. ICU length of stay and major complications,
such as hemorrhage, tracheotomy, ICU-acquired infection
or need for emergency surgery, were also collected.
Biological variables
The results of the iron profile routinely obtained on the
day of ICU discharge were collected. Normal ranges for
biological data are shown in Table 1. All hematological
variables were obtained using an automated analyzer
(Sysmex®, Villepinte, France). Serum iron was determined
by the colorimetric method. Transferrin was deter-
mined by nephelometry. Ferritin was determined by
chemiluminescent microparticle immunoassay with
Architect i2000®, Abbot (Abbot, Rungis, France).
Transferrin saturation was calculated as serum iron/
total iron binding capacity x 100. The investigators
who assessed fatigue and muscular strength (see
below) were blinded to iron status.
Definitions of iron deficiency
Iron deficiency was defined as a serum ferritin concen-
tration of less than 100 μg/L or as a transferrin satur-
ation of less than 20% together with a serum ferritin
concentration of less than 300 μg/L, according to the def-
inition used in a recent interventional study [21] and by
cardiologists [22,23].Outcome and fatigue evaluation
On ICU discharge, fatigue was assessed using a visual
analog scale (VAS) with a result ranging from 0 (‘not
tired’) to 100 (‘exhausted’) and by a numerical scale
(patients were asked to grade their fatigue from 0 (‘not
tired’) to 10 (‘exhausted’) (scores were then multiplied
by 10). Hand grip tests were performed to assess muscu-
lar strength: patients were asked to squeeze a dynamom-
eter with as much force as possible three times with
their dominant hand and three times with their non-
dominant hand. The best observed value was recorded.
The observed value was compared with normal values
according to age and gender [24]. The percentage of
strength reduction was calculated using normal values
according to age and gender as follows: % strength re-
duction = (theoretical value - measured value)/ theoretical
value [24].
Table 1 Hematological and iron parameters on ICU admission and discharge according to iron deficiency status on ICU
discharge and on D28 and at M6
Parameters Normal ranges On ICU admission On ICU discharge
ID (number = 9) Non-ID (number = 98) P ID (number = 9) Non-ID (number = 98) P
Red blood cells (1012/L) 4.5 to 5.8 4.0 ± 0.6 3.7 ± 2.6 0.15 3.2 ± 0.6 3.7 ± 2.6 0.21
Hb (g/dL) 13.5 to 17.5 12.3 ± 1.7 11.2 ± 2.4 0.12 9.3 ± 1.5 10.1 ± 1.3 0.08
Hematocrit (%) 40 to 50 37.0 ± 4.8 33.5 ± 6.9 0.09 28 ± 5 34 ± 27 0.09
MCV (f/L) 82 to 98 91.7 ± 3.9 90.2 ± 8.5 0.58 89.3 ± 3.7 90 ± 3.8 0.38
MCHC (g/dL) 32 to 36.5 32.9 ± 1.9 33.1 ± 1.5 0.51 32.8 ± 1.2 32.8 ± 1.3 0.44
Reticulocyte count (109/L) 20 to 100 37 ± 13 51 ± 35 60 ± 34 0.67
Serum iron (μmol/L) 12 to 30 6.0 ± 4.1 6.1 ± 3.4 0.80
Ferritin (μg/L) 100 to 350 196 (174 to 208) 699 (497 to 1008) 0.0001
Transferrin (g/L) 1.6 to 3.2 1.8 ± 0.5 1.6 ± 0.6 0.19
TSAT (%) 20 to 40 9 (9 to 13) 14 (10 to 19) 0.09
Data are presented as mean ± SD or medians (Q1 to Q3). Hb, hemoglobin; ID, iron deficiency; MCHC, mean corpuscular hemoglobin concentration; MCV, mean
corpuscular volume; non-ID, no iron deficiency; TSAT, transferrin saturation. Values in italic are p values.
Lasocki et al. Critical Care 2014, 18:542 Page 3 of 9
http://ccforum.com/content/18/5/542Patients were then followed up on day 28 (D28) and
6 months (M6) after ICU discharge. At these time points,
fatigue was assessed by the Multidimensional Fatigue
Inventory score (MFI-20) and by the numerical scale
of fatigue. MFI-20 is a 20-item self-reporting score
designed and validated to measure fatigue [25]. MFI-20
measures fatigue using five dimensions: general fatigue,
physical fatigue, mental fatigue, reduced motivation and
reduced activity. High MFI scores indicate high degrees
of fatigue. However, we used the French validated ver-
sion of the score in which only four dimensions are
described (general fatigue (score ranges from 0 to 45),
mental fatigue (0 to 30), reduced activity (0 to 15) and
reduced motivation (0 to 10)) [26].
Finally, patients were asked to test their blood count,
ferritin and transferrin saturation levels at independent
laboratories on D28 and at M6. Medical prescriptions
were mailed to the patients one week before the scheduled
date (for patients no longer in the hospital), and patients
were reminded of the need for blood panels during the
phone call for assessment of fatigue.
Statistical analysis
Data were analyzed using Stata version 12.1 (StataCorp,
College Station, Texas, USA). Data are presented as me-
dians with inter-quartile ranges (first to third quartile) or
mean ± standard deviation (SD) for continuous variables
and as a percentage for categorical variables.
Owing to insufficient data available to develop a satisfac-
tory working hypothesis, an arbitrary sample size of one
hundred patients was selected with an expected preva-
lence of ID of approximately 30% to 40%.
For the analysis, patients were separated into two groups:
ID and no ID (non-ID), at the different time points evalu-
ated (that is, ICU discharge, D28 and M6).The primary end point was the comparison of the differ-
ent fatigue scales and the strength of patients with and
without ID on ICU discharge using the Wilcoxon test.
The fatigue of ID and non-ID patients was also com-
pared on D28 and at M6. Linear regression models were
created to evaluate the association between ID and fatigue
on D28 and at M6. Various covariables were added to the
model based on clinical judgment (ID, age, gender, SOFA,
length of ICU stay, Hb on ICU discharge, type of admis-
sion, anemia, catecholamine, transfusion). The covariables
retained in the model were then chosen according to the
Akaike criteria. Continuous covariates included in the
linear model were dichotomized when their effect could
not be considered as linear. Finally, the model was vali-
dated by normalization of the residuals. The covariates
finally included were presence of ID, age (dichotomized
as < or ≥60 years), gender, SOFA (dichotomized as < or ≥7,
which was the median SOFA score), length of ICU stay
(<or ≥10 days, which was also the median length of stay),
low Hb (that is, <10 g/dl).
We also created a mixed longitudinal model to evaluate
the probability of ID and anemia over time after ICU dis-
charge (with time as a fixed variable and patients as a ran-
dom variable). P <0.05 was considered statistically significant.
Results
During the study period, 475 patients admitted to the par-
ticipating ICUs were eligible. Finally, 113 were included in
the study and 107 had an iron profile fully available for ID
diagnosis on ICU discharge. We were able to follow up 80
(75%) patients on D28 and 78 (73%) at M6 (see Figure 1 for
the study flowchart). The demographic and clinical charac-
teristics of the ID and non-ID patients were not different
(Table 2). Median Hb concentration on ICU admission was
11.1 (9.3 to 12.9) g/dL. During their ICU stay, 29 (26%)
Figure 1 Study flow chart. ICU: intensive care unit; D28: 28 days
after discharge; M6: 6 months after discharge.







Age (years) 64 ± 18 59 ± 18 0.45
Body mass index (kg/m2) 29.7 ± 9.3 26.9 ± 6.9 0.50
SAPS II 52 ± 25 45 ± 18 0.59
SOFA 9 ± 5 7 ± 4 0.39
ICU length of stay (days) 11 ± 9 15 ± 12 0.39
Men 6 (67%) 77 (79%) 0.42
Type of admission 0.9
- unplanned surgical 6 (67%) 61 (62%)
- scheduled surgery 1 (11%) 16 (16%)
- medical 2 (22%) 21 (21%)
Trauma 3 (33%) 20 (20%) 0.2
Hemorrhage 2 (22%) 26 (27%) 1
Mechanical ventilation 8 (89%) 90 (92%) 0.56
Renal replacement therapy 2 (22%) 19 (19%) 1
ICU-acquired infection 2 (22%) 39 (40%) 0.48
Iron supplementation 2 (22%) 2 (2%) 0.035
Red blood cell transfusion 3 (33%) 55 (56%) 0.30
Vasopressors 8 (89%) 64 (65%) 0.27
Data are presented as means ± SD or number (%).Hemorrhage was defined as
a loss of 3 or more g/dl of Hb and/or the need for 3 or more PRBC units in
fewer than 6 hours, together with a clinical source of bleeding. Iron
supplementation is the use of any iron preparation (either intravenous or oral).
ICU: intensive care unit; ID: iron deficiency; non-ID: no iron deficiency; PBRC:
packed red blood cells; SAPS II: Simplified Acute Physiology Score II; SOFA:
Sequential Organ Failure Assessment. Values in italic are p values.
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required a median of 2 (0 to 4) units of packed red blood
cell transfusions, without a difference between ID and non-
ID patients.
Prevalence of iron deficiency and anemia on discharge,
D28 and M6
On ICU discharge, nine (8.4%) patients had ID with
lower ferritin levels than the non-ID patients, but both
groups had similar Hb concentrations (Tables 1 and 3).
It should be noted that transferrin saturation remained
low in both groups, indicating low iron availability in
critical care patients. Interestingly, this prevalence of ID
increased with time (P <0.0001) together with a decrease
in anemia prevalence (P <0.0001). Twenty (25%) patients
had ID on D28, and 27 (35%) at M6. We observed an
increase in Hb levels from ICU discharge up to six months
together with a continuous decrease in ferritin levels.
However, 80% of the patients were still anemic on D28
and 25% at M6 (Figure 2).
Muscular weakness and fatigue on ICU discharge
Hand grip strength was decreased on ICU discharge:
median hand grip test was 44 pounds (IQR: 26 to 63)and median percentage of strength reduction was 51%
(28% to 67%) depending on age and gender. Eleven
(10%) patients had a strength reduction of more than
80%. However, this decrease was similar in ID and non-ID
patients (40% ±27% versus 45% ±33% for ID and non-ID
patients, P =0.27).
Fatigue assessed by a VAS and by a numerical scale of
fatigue was high (55 (35 to 75)/100 and 50 (40 to 80)/100,
respectively). We found a significant correlation between
VAS and numerical scale of fatigue (R2 = 0.73 (95%CI;
0.62 to 0.81), P <0.0001). Only 26 (23%) patients had a
VAS ≤35/100. ID and non-ID patient fatigue was similar
(mean VAS 51 ± 35 versus 57 ± 24, for ID and non-ID
patients, respectively, P =0.81).
Outcome and fatigue on D28 and at M6
On D28, only 31 (30%) patients were alive and at home.
There was a similar proportion between ID and non-ID
patients (P =0.72). Ten (9%) patients, including one ID
patient, died before D28. Two patients refused to respond
to the questionnaires at six months (78 patients evaluated).
On D28, two ID patients were lost to follow-up (among a
total of 27 patients lost), and three (among 29) at M6.
Table 3 Iron indices and Hb values on D28 and at M6
Normal ranges On D28 At M6
ID (number = 20) Non-ID (number = 60) P ID (number = 27) Non-ID (number = 51) P
Hb (g/dL) 13.5 to 17.5 11.5 (10.4 to 11.9) 11.3 (9.85 to 12.35) 0.26 13.6 (12 to 14.4)] 13.4 (12.2 to 14.1) 0.63
Ferritin (μg/L) 100 to 350 207 (98 to 269) 522 (346 to 816) <0.0001 238 (167 to 407) 78(56 to 96) <0.0001
TSAT (%) 20 to 40 14.5 (11 to 18.5) 0.002 26.8 (23 to 34) 16 (11.7 to 24) <0.0001
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assessed by the MFI-20 at D28, with increased mental
fatigue and reduced activity scores. Patients with ID on
D28 also had higher MFI-20 fatigue scores in mental
fatigue and reduced activity dimensions on D28 (Figure 3).
At M6, ID was not associated with increased fatigue. We
created multivariate linear regression models to study the
link between each sub-dimension of the MFI-20 question-
naire on D28 and ID status, age, Hb and SOFA score,
gender and ICU length of stay (LOS). ID was associated
with mental fatigue on D28 and with reduced activity
(Table 4). Age over 60 was associated with less mental
fatigue, whereas an Hb of less than 10 g/dl was associated
with increased general fatigue. At six months, these asso-
ciations were not present. Evaluation of fatigue using the
numerical scale showed no difference on D28 and at M6.
Discussion
In this prospective observational study, we found that
the prevalence of ID on ICU discharge was approximately
10% and increased after discharge to 35% at six months.
On D28, ID was associated with increased fatigue (mental
fatigue and reduced activity) but not with Hb levels.
To our knowledge, this is the first study investigating
the prevalence of ID on ICU discharge. There are few data
available concerning ID on ICU admission. Some studies
have assessed ID on admission and found the prevalence
between 9% and 38% [7-14]. These studies used differentFigure 2 Evolution of anemia and iron stores after ICU discharge. The
after ICU discharge, showing an increasing ID prevalence together with a d
ferritin and hemoglobin levels after ICU discharge. Ferritin levels (expressed
until M6, whereas Hb levels (medians (Q1 to Q3)) increased. D28, 28 days aID definitions. Bellamy et al. found a prevalence of 35%
using the percentage of hypochromic red cells [7] and
Fernandez et al., a prevalence of 37% using the reticulo-
cyte Hb content [8]. In a previous study, assessing ID
using different biomarkers (that is, soluble transferrin
receptor, zinc protoporphyrin, transferrin saturation and
ferritin) and a consensus of three experts, we found an ID
prevalence of 10% on study inclusion and 26% during the
ICU stay [9]. In the present study, the prevalence of ID
is relatively low. Indeed, because of the blood losses
regularly observed in critically ill patients (approximately
40 ml/day [15]), one could have expected a higher preva-
lence of ID. In our study, 26% of the patients suffered
from hemorrhage and 54% required packed red blood cell
transfusions during their ICU stays – suggesting sig-
nificant blood losses. However, ID diagnosis is difficult in
the context of inflammation [5,27]. Indeed, on ICU dis-
charge, we observed very high ferritin concentrations in
our cohort. There is no consensus to define ID in critically
ill patients [5,27]. Thus, we choose to use an ID definition
that has already been used in an intervention study [21]
and that is commonly accepted in cardiac patients [22,23].
However, we could have used more recent biological
markers that have been proposed for ID diagnosis in the
presence of inflammation [28]. The most reliable test
appears to be the percentage of hypochromic red cells, a
value of more than 10% (normal: less than 2.5%) being
indicative of a functional iron deficiency [28-30].left panel represents the prevalence of anemia and iron deficiency
ecreasing anemia prevalence. The right panel shows the evolution of
as median and inter-quartile ranges) decreased from ICU discharge
fter discharge; ID: iron deficiency; M6, 6 months after discharge.
Figure 3 MFI-20 scores in patients with ID on ICU discharge (Panel A) and on D28 (Panel B). There is an association between ID, both on
discharge and at D28, and higher mental fatigue and reduced activity scores. Data presented are means of each fatigue dimension. *P <0.05. D28,
day 28; ID, iron deficiency; MFI-20, multidimensional fatigue inventory-20 items.
Lasocki et al. Critical Care 2014, 18:542 Page 6 of 9
http://ccforum.com/content/18/5/542Reticulocyte Hb content, with a value less than 29 pg, has
also been proposed [8,28,31]. Unfortunately, these two pa-
rameters are no longer usable in the case of blood transfu-
sion, which concerns more than half of our patients.
Soluble transferrin receptor is also proposed as an ID
marker in the presence of inflammation [32,33]. Elevated
soluble transferrin receptor reflects high bone marrow
erythropoietic activity in the presence of low iron supply.
However, there is no reference value and it was routinely
available only at two centers out of four. Given these un-
certainties, new biological markers should probably be de-
veloped and hepcidin could be one of them [9]. Hepcidin
is a negative regulator of intestinal iron absorption and
iron recycling by macrophages. Its synthesis is induced by
inflammation and it plays a key role in the anemia of in-
flammation [6]. Plasma hepcidin levels are strongly re-
pressed by ID and following stimulation of erythropoiesis,
even in the presence of inflammation [34].Even if the reported prevalence of ID on discharge is
relatively low, we report for the first time much higher
ID prevalence after discharge (at one and six months),
with almost one-third of the patients suffering from ID
at M6. In a previous study, out of 19 critical care anemic
patients followed up for six months, Bateman et al. ob-
served relatively low ferritin levels at six months (76 (24
to 179) μg/L) [35], in accordance with the high propor-
tion of ID we report. Interestingly, the prevalence of ID
increased after ICU discharge together with an increase
in Hb levels, leading to the appearance of ID without
anemia. This was also observed in the Bateman study
[35]. This could be interpreted as iron being mobilized
from stores to the circulating Hb. Indeed, iron absorp-
tion may not be sufficiently increased owing to persistent
inflammation with elevated hepcidin levels. This could
also explain the persistence of anemia in some critically ill
patients [35].
Table 4 Multivariate analysis of factors associated with
MFI-20 fatigue dimensions on D28
MFI-20 fatigue dimensions Regression Coefficient (95% CI) P
Mental fatigue
ID 3.19 (0.74; 5.64) 0.012
Age (>60 years) -1.81 (-3.49; -0.13) 0.035
Hb (<10 g/dl) -0.11 (-1.7; 1.48) 0.89
SOFA (>7) 1.62 (-0.12; 3.36) 0.068
Gender (male) 0.95 (-1.01; 2.92) 0.34
ICU LOS (>10 days) -0.48 (-2.05; 1.10) 0.55
General fatigue
ID -2.12 (-4.41; 0.16) 0.068
Age (>60 years) 0.35 (-1.22; 1.92) 0.66
Hb (<10 g/dl) 1.82 (0.36; 3.29) 0.016
SOFA (>7) 0.86 (-0.75; 2.47) 0.29
Gender (male) 0.07 (-1.69; 1.83) 0.94
ICU LOS (>10 days) 1.08 (-0.37; 2.53) 0.14
Reduced activity
ID 1.24 (-0.11; 2.59) 0.07
Age (>60 years) -0.21 (-1.15; 0.72) 0.65
Hb (<10 g/dl) -0.36 (-1.22; 0.51) 0.41
SOFA (>7) 0.57 (-0.38; 1.52) 0.23
Gender (male) 0.61 (-0.42; 1.65) 0.24
ICU LOS (>10 days) 0.58 (-0.27; 1.44) 0.18
Reduced motivation
ID -1.25 (-3.06; 0.55) 0.17
Age (>60 years) -0.28 (-1.51; 0.96) 0.66
Hb (<10 g/dl) 0.38 (-0.81; 1.49) 0.56
SOFA (>7) -0.03 (-1.29; 1.24) 0.97
Gender (male) 0.35 (-1.04; 1.73) 0.62
ICU LOS (>10 days) -0.39 (-1.53; 0.75) 0.49
A linear regression model was created including: ID on ICU discharge, age
(<or ≥60 years), gender (male), SOFA (<or ≥7), ICU LOS (<or ≥10 days), low Hb
(HbD28 < 10 g/dl) (model 1). Data are presented as OR with 95% confidence
interval. Hb: hemoglobin; ICU: intensive care unit; ID: iron deficiency; LOS:
length of stay;.MFI: multidimensioal fatigue inventory; SOFA: Sequential Organ
Failure Assessment score. Values in italic are p values.
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discharge and persisted on D28. Less than a quarter of
our critically ill patients had a VAS of fatigue <35/100.
On D28, fatigue was still significant as suggested by high
MFI-20 scores and a low proportion of patients had
returned home. Despite these results, we were unable to
find any association between ID and fatigue on ICU dis-
charge. There were probably too many confounding fac-
tors for fatigue on ICU discharge, such as anemia, ID,
neuromuscular weakness, muscular edema and so on.
Importantly, fatigue persisted on D28 and was associated
with ID, independently of Hb. The relation between ID
and fatigue or muscular weakness has been widely studied[36]. In cardiac surgery, for example, preoperative ID is
associated with a significant increase in the physical fa-
tigue dimension of the MFI-20 score seven days after sur-
gery [16]. In a cohort of 28,000 women, ID was associated
with fatigue and decreased general health scores [37]. Re-
cent data have demonstrated the benefit of ID treatment
on fatigue, for example, in patients with chronic heart fail-
ure even in the absence of anemia [21]. In non-anemic
women, treatment of ID also improves fatigue scores
compared with placebo [19]. Surprisingly, this relation
between fatigue and ID was not confirmed at six
months. This could be due to the definition of ID used.
Indeed, ferritin concentration is dependent on the level
of iron stores but also on the degree of inflammation.
At D28, a ferritin concentration less than 100 μg/l is
probably indicative of lower iron stores than at M6 when
inflammation is expected to be lower and, thus, ferritin
too. However, because we did not assess inflammation,
this is only hypothetical. It is also possible that the asso-
ciation between ID and fatigue was observed by chance
on D28.
Treatment of ID in critically ill patients may be pro-
posed to compensate for anemia correction and to im-
prove patient fatigue. Until recently, the potential benefit
of iron was considered as being counterbalanced by its
potential harm, including oxidative stress induction and
infectious disease risk. Indeed, one experimental study
showed increased mortality associated with high-dose iron
treatment [38]. However, using therapeutic doses of iron,
we found no sign of toxicity in a mouse model of critical
care anemia [39] and one study of oral iron treatment in
the critically ill reported a reduction in transfusion risk
with no increased side effects [11]. However, further ex-
plorations are needed to confirm this hypothesis.
Our study has several limitations. First, despite a total
number of 113 patients included in the study, iron profiles
were available in only 107 patients. This is due to the
observational design of the study. Second, we did not
measure iron markers on admission or inflammatory
markers, such as interleukin-6 or C-reactive protein, on
day 28 and at M6. We hypothesize that high ferritin con-
centrations are related to a persistent inflammatory status
but we cannot confirm it biologically and the diagnosis of
ID (that is, the threshold of ferritin for ID) could have
been modulated according to the degree of inflammation.
This could be of crucial importance at M6 when inflam-
mation is expected to be lower. As discussed above, hepci-
din could have been helpful to determine ID. Third, the
study is limited in that it is an observational study and,
therefore, causality cannot be inferred and because of
the relatively low number of patients, multiple adjust-
ments for all comorbidities could not have been performed.
Finally, we did not measure hand grip strength on D28 and
at M6 owing to logistical issues.
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In conclusion, in our study population of surgical ICU
patients, the prevalence of ID on ICU discharge was
approximately 10%, underscoring the difficulty of ID diag-
nosis in this context. ID prevalence increases to more than
one-third at six months and is associated with fatigue at
one month, independently of Hb levels. Further studies
are needed to evaluate the benefit of iron treatment on
ICU discharge. In addition, the usefulness of other ID
markers, such as hepcidin, should be investigated.
Key messages
 The prevalence of ID was approximately 10% on
ICU discharge.
 The prevalence of ID increased to 35% at six
months.
 A quarter of the critically ill patients were still
anemic at six months.
 ID was associated with increased fatigue one month
after ICU discharge, independently of low Hb levels.
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